

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,008,633 B2  
APPLICATION NO. : 10/024678  
DATED : March 7, 2006  
INVENTOR(S) : David J. Yang et al.

Page 1 of 2

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title page, left column, under [75] Inventors: . . . Ali Azhdarinia, Houston, TX (US) should be on the same line.

Title page, left column, under [75] Inventors: . . . E. Edmund Kim, Houston, TX (US) should be on the same line.

In Col. 67, line 56, after the third occurrence of "hormone" insert -- releasing hormone --.

In Col. 67, line 59, after "gonadotropin" insert -- , somatotropin, somatostatin, somatotropin releasing hormone, gonadotropin --.

In Col. 67, line 67, "erthropoetin" should read -- erythropoietin --.

In Col. 68, line 1, "estradiol" should read -- estradiol --.

In Col. 68, line 5, "enkaepalin" should read -- enkephalin --.

In Col. 68, line 10, "platlet-derived" should read -- platelet-derived --.

In Col. 68, lines 22-23, "*ras ; myc, raf, erb, src, fms, jun, trk, ret, gsp, hst, bcl abl,*" apply Italic font.

In Col. 68, line 24, "ras" apply Italic font.

In Col. 68, line 33, after the occurrence of "claim" delete "of".

In Col. 68, line 41, "bromelam" should read -- bromelain --.

In Col. 68, line 44, "aurantiurn" should read -- aurantium --.

In Col. 68, line 58, "picrorbiza" should read -- picrorhiza--.

In Col. 68, line 61, "chiorophyllin" should read -- chlorophyllin --.

In Col. 68, line 66, "in situ" apply Italic font.

In Col. 68, line 5, "in situ" apply Italic font.

In Col. 69, line 6, "cross linked" should read -- cross-linked --.

In Col. 69, line 10, after the "container" insert -- cthe cross-linking composition. --.

In Col. 69, line 34, "polyainino" should read -- polyamino --.

In Col. 70, line 2, "vinbiastine" should read -- vinblastine --.

In Col. 70, line 3, "meiphalan" should read -- melphalan --.

In Col. 70, line 20, "acetyicholine" should read -- acetylcholine --.

In Col. 70, line 22, "chymodemn" should read -- chymodenin --.

In Col. 70, line 26, "choriome" should read -- chorionic --.

In Col. 70, line 29, "lysyibradykinin" should read -- lysylbradykinin --.

In Col. 70, line 37, "P." should read -- P, --.

In Col. 70, line 46-47, "*ras ; myc, raf, erb, src, fms, jun, trk, ret, gsp, hst, bcl abl, Rb,*" apply Italic font.

In Col. 70, line 67, "chiorella" should read -- chlorella --.

In Col. 71, line 2, "QIO" should read -- Q10 --.

In Col. 71, line 13, "ocinium" should read -- ocimum --.

In Col. 71, line 14, "pay" should read -- pau --.

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,008,633 B2  
APPLICATION NO. : 10/024678  
DATED : March 7, 2006  
INVENTOR(S) : David J. Yang et al.


Page 2 of 2

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In Col. 71, line 21, "vohimbe" should read -- yohimbe --.  
In Col. 71, line 41, "svrinaes" should read -- syringes --.  
In Col. 71, line 58, "polyglutaxnate" should read -- polyglutamate --.  
In Col. 71, line 63, "Ra.<sup>2+</sup>, or Be<sup>2+</sup>." should read -- Ra<sup>2+</sup>, Sn<sup>2+</sup>, or Be<sup>2+</sup>. --.  
In Col. 72, line 27, "meiphalan" should read -- melphalan --.  
In Col. 72, line 31, after the occurrence of "trimethoprim," insert -- metronidazole, clindamycin, mupirocin, amphotericin B, rifampin, fluconazole, or a combination thereof. --.  
In Col. 72, line 41, "epmephrine" should read -- epinephrine --.  
In Col. 72, line 42, "acetyicholine" should read -- acetylcholine --.  
In Col. 72, line 43, "vasopressin." should read -- vasopressin, --.  
In Col. 72, line 43, "bradykinin." should read -- bradykinin, --.  
In Col. 72, line 47, "amuibutyric" should read -- aminobutyric --.  
In Col. 72, line 59, "thymopoietin." should read -- thymopoietin, --.  
In Col. 73, line 2-3, "*ras ; myc, raf, erb, src, fms, jun, trk, ret, gsp, hst, bcl abl*," apply Italic font.  
In Col. 74, line 22, "in situ" apply Italic font.  
In Col. 74, line 29, "in situ" apply Italic font.

Signed and Sealed this

Seventh Day of October, 2008



JON W. DUDAS  
Director of the United States Patent and Trademark Office